Medifast (MED) Tops Q4 EPS by 24c, Misses on Revenue; Offers Q1 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Medifast (MED) PT Lowered to $16.50 at DA Davidson
February 19, 2025 1:01 PM ESTDA Davidson analyst Linda Bolton Weiser lowered the price target on Medifast (NYSE: MED) to $16.50 (from $17.00) while maintaining a Neutral rating.
The analyst comments "NEUTRAL-rated MED reported a 4Q24 beat. In December, it launched the Ascend line for people who were... More
